Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for refractory chronic migraine
NCT03896256Phase 1Completed
- Sponsor
- Thomas Jefferson University
- Start
- Mar 2019
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ketamine in migraine, sponsored by Thomas Jefferson University. Primary endpoints: Numerical Rating Scale at 1 year and Qualitative Pain Assessment Scale at 1 year. Started Mar 2019; status: completed.
02
Drugs
ketamine
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03896256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896256.